CDE100 association

Phase 3Small molecule

EEMS

CDE100 association is one of 26 small molecule programs targeting Dysmenorrhea. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DysmenorrheaRecruiting

DysmenorrheaPhase 3

Recruiting

Competition

Competitive Landscape

30 competitors in Dysmenorrhea

#DrugCompanyPhaseTrials

Aleve

Jazz Pharmaceuticals

Approved

2 2

Voltaren

Novartis

Approved

1 3

Voltaren

Novartis

Approved

1 4

Estrace

Bayer Aspirin

Tylenol

2 7

Bextra

TThe Searle Company Limited Pakistan

Approved

1 8

Ultram

WWim Janssens

Approved

1 9

Oruvail

WWyeth-Lederle Vaccines

Approved

—10

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Dysmenorrhea

NCT05640232

Clinical

Trials by Indication[1]

Dysmenorrhea1 trial

Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea

Recruiting·EEMS·Phase 3·NCT05640232·238 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CDE100 association. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CDE100 association compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CDE100 association. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EMS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEMS

CDE100 association

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Dysmenorrhea1 trial

References

Drug Info

Quick Facts

Related News